A multipeptide vaccine plus toll-like receptor agonists in melanoma patients, with evaluation of the vaccine site microenvironment and sentinel immunized node (Mel58; NCT01585350).

Authors

Craig Slingluff

Craig L. Slingluff Jr.

University of Virginia School of Medicine, Charlottesville, VA

Craig L. Slingluff Jr., Gina R. Petroni , Kimberly A. Chianese-Bullock , William W. Grosh , Geoffrey R. Weiss

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics - Immunotherapy

Track

Developmental Therapeutics

Sub Track

Vaccines

Clinical Trial Registration Number

NCT01585350

Citation

J Clin Oncol 31, 2013 (suppl; abstr TPS3125)

DOI

10.1200/jco.2013.31.15_suppl.tps3125

Abstract #

TPS3125

Poster Bd #

24D

Abstract Disclosures

Similar Posters

Poster

2019 ASCO Annual Meeting

A phase 1/2a study of GEN-009, a neoantigen vaccine based on autologous peptide immune responses.

A phase 1/2a study of GEN-009, a neoantigen vaccine based on autologous peptide immune responses.

First Author: Roger B. Cohen

First Author: Richard Eldon Royal